Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05467930 · ClinicalTrials.gov registry record
CU-COMMITS: COVID-19 Care in Black and Latino Communities and Households. Clinical and Molecular Outcomes of SARS-CoV-2
A clinical trial of COVID-19 and SARS CoV 2 Infection, sponsored by Columbia University.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT05467930 is a study of COVID-19 and SARS CoV 2 Infection that is actively recruiting participants, run by Columbia University. The registered enrollment target is 1,000 participants, below the 55,210-participant average among 203 other COVID-19 trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05467930, a study of COVID-19 and SARS CoV 2 Infection, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to describe the long-term health effects of COVID-19 in a population of mostly Black and Latinx individuals and their households who were diagnosed with COVID-19 at Columbia University Irving Medical Center. In New York, the upper Manhattan and south Bronx communities neighboring Columbia University Irving Medical Center (CUIMC) have been two of the most impacted communities of the COVID-19 pandemic. These neighborhoods are predominantly non-Hispanic black or African American and Latinx. This study will invite people who tested positive for COVID-19 and/or were treated at Columbia University Irving Medical Center to: 1) take a survey to ask about current symptoms and any health problems and 2) ask permission to review COVID-related health history including COVID-19 testing results (from the medical record) since infection to learn about health effects after COVID-19 infection; 3) invite anyone in their household to take a survey; and 4) for up to 500 patients who were hospitalized for COVID, give the option of doing a nasal swab to test for SARS-CoV-2 virus and blood test to check for antibody up to 12 months after diagnosis, to compare how results are different 12 months after infection. The goal is to learn about how the severity of person's infection in 2020 influences long term health effects and how others in their household are impacted by COVID-19.
Conditions Studied
Interventions
- OTHER Survey
- OTHER Sample Collection
- OTHER Medical History Review
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2021-07-01 |
| Est. Completion | 2027-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05467930
The ClinicalTrials.gov registry entry for NCT05467930 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,210-participant average among 203 other COVID-19 trials with a reported enrollment target (98% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with COVID-19 appearing as the primary indexed condition, and to 3 interventions - of which Survey is the first listed.
NCT05467930 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05467930 about?
NCT05467930 is a clinical study titled "CU-COMMITS: COVID-19 Care in Black and Latino Communities and Households. Clinical and Molecular Outcomes of SARS-CoV-2". The purpose of this study is to describe the long-term health effects of COVID-19 in a population of mostly Black and Latinx individuals and their households who were diagnosed with COVID-19 at Columbia University Irving Medical Center. In New York, the upper Manhattan and south Bronx communities ne...
What is the current status of trial NCT05467930?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2021-07-01. Estimated completion is 2027-05.
What conditions does trial NCT05467930 study?
This clinical trial studies the following conditions: COVID-19, SARS CoV 2 Infection.
What interventions are being tested in trial NCT05467930?
The interventions under investigation include: Survey (OTHER), Sample Collection (OTHER), Medical History Review (OTHER).
Who is sponsoring clinical trial NCT05467930?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05467930 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
The Impact of COVID-19 on Maternal and Neonatal Outcomes
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.